
Aptevo Therapeutics APVO
$ 4.96
4.64%
Annual report 2025
added 03-26-2026
Aptevo Therapeutics DIO Ratio 2011-2026 | APVO
Annual DIO Ratio Aptevo Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 112 | 58.1 | 74.9 | 100 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 112 | 58.1 | 86.4 |
Quarterly DIO Ratio Aptevo Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 167 | 86.2 | 72.7 | - | 66.8 | 64.3 | 72.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 167 | 64.3 | 88.1 |
DIO Ratio of other stocks in the Biotechnology industry
| Issuer | DIO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Alexion Pharmaceuticals, Inc.
ALXN
|
512 | - | - | $ 40.3 B | ||
|
BeiGene, Ltd.
BGNE
|
304 | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
125 | - | - | $ 546 M | ||
|
Midatech Pharma plc
MTP
|
40.6 | - | -18.52 % | $ 27.3 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
166 | $ 21.41 | 0.21 % | $ 1 B | ||
|
Институт стволовых клеток человека
ISKJ
|
275 | - | - | - | ||
|
Aeterna Zentaris
AEZS
|
55.6 | - | 5.93 % | $ 314 M | ||
|
Akebia Therapeutics
AKBA
|
147 | $ 1.53 | 4.08 % | $ 393 M | ||
|
Aquestive Therapeutics
AQST
|
120 | $ 4.15 | -0.95 % | $ 444 M | ||
|
Arcutis Biotherapeutics
ARQT
|
185 | $ 25.2 | 4.48 % | $ 3.21 B | ||
|
Autolus Therapeutics plc
AUTL
|
70.7 | $ 1.5 | 2.04 % | $ 399 M | ||
|
AstraZeneca PLC
AZN
|
206 | - | - | $ 96.9 B | ||
|
Grifols, S.A.
GRFS
|
0.000171 | $ 8.56 | 2.39 % | $ 6.83 B |